Italian tumour marker licensed to Antisoma
This article was originally published in Clinica
Executive Summary
A monoclonal antibody against angiogenesis developed by the National Institute of Cancer Research in Genoa, Italy, has been licensed to UK biotechnology company Antisoma. In return for exclusive worldwide rights, Antisoma has made an undisclosed payment and will pay royalties on resulting commercial products.